NEW YORK – Biotech Immunome has given the first patient with a solid tumor its fibroblast activation protein (FAP)-targeted radioligand therapy within a clinical trial, the company announced Monday.

If approved after priority review, the firm anticipates launching DYNE-251 in the US in the first quarter of next year.

The trial will include patients with relapsed or refractory B-cell malignancies, including patients who have received prior CAR T-cell therapies.

The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...

Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...

After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...

The focus on treating people who have no cognitive impairment raises questions about how to implement testing for those at ...

A panel determined that Tafinlar and Adcetris will be offered to certain patients but passed on several other precision therapies.

Primary care docs in Sweden diagnosed Alzheimer's with the same accuracy as dementia specialists when they had access to beta ...

NEW YORK – Servier is acquiring Day One Biopharmaceuticals in a deal worth approximately $2.5 billion that is expected to bolster Servier's portfolio of targeted oncology therapeutics, the firms ...

NEW YORK – Callio Therapeutics on Tuesday started treating patients in a Phase I trial of its dual payload antibody-drug conjugate (ADC) CLIO-8221 in patients with advanced HER2-expressing solid ...